Collegium Pharmaceutical (NASDAQ: COLL)
FY 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-12-20 | ||||||
REV |
FY 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-11-09 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Collegium Pharmaceutical (NASDAQ: COLL) through any online brokerage.
Other companies in Collegium Pharmaceutical’s space includes: Atea Pharmaceuticals (NASDAQ:AVIR), Theravance Biopharma (NASDAQ:TBPH), GH Research (NASDAQ:GHRS), SNDL (NASDAQ:SNDL) and Aerie Pharmaceuticals (NASDAQ:AERI).
The latest price target for Collegium Pharmaceutical (NASDAQ: COLL) was reported by Cantor Fitzgerald on Friday, August 12, 2022. The analyst firm set a price target for 4.00 expecting COLL to fall to within 12 months (a possible -78.72% downside). 50 analyst firms have reported ratings in the last year.
The stock price for Collegium Pharmaceutical (NASDAQ: COLL) is $18.8 last updated August 12, 2022, 8:00 PM UTC.
The next Collegium Pharmaceutical (COLL) dividend date is projected to be Thursday, September 1, 2022.
Collegium Pharmaceutical’s FY earnings are confirmed for Wednesday, December 20, 2023.
There is no upcoming split for Collegium Pharmaceutical.
Collegium Pharmaceutical is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.